Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study

References

• Lauer S, Gardner JM. Soft tissue sarcomas-new approaches to diagnosis and classification. Curr Probl Cancer. 2013;37(2):45–61. doi:10.1016/j.currproblcancer.2013.03.001
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Delank S, Eich H. Multimodality therapy concepts for soft tissue sarcomas. Internist (Berl). 2010;51(11):1388–96. doi:10.1007/s00108-010-2672-8
   PubMed Web of Science ®Google Scholar
• Shi Y. Chinese expert consensus on diagnosis and treatment of soft tissue sarcoms (Version 2015). Chinese J Oncol. 2016;38(4):310–4.
   Google Scholar
• von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Conrad EU 3rd, Ganjoo KN, George S, Gonzalez RJ, Heslin MJ, et al. Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(6):758–86. doi:10.6004/jnccn.2016.0078
   PubMed Web of Science ®Google Scholar
• Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 2010;70(20):7981–91. doi:10.1158/0008-5472.CAN-10-0111
   PubMed Web of Science ®Google Scholar
• Ji G, Hong L, Yang P. Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case report. Onco Targets Ther. 2016;9:643–7. doi:10.2147/OTT.S96133
   PubMed Web of Science ®Google Scholar
• Dong M, Bi J, Liu X, Wang B, Wang J. Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case report. Medicine (Baltimore). 2016;95(31):e4368. doi:10.1097/MD.0000000000004368
   PubMed Web of Science ®Google Scholar
• Ji G, Hong L, Yang P. Successful treatment of angiosarcoma of the scalp with apatinib: a case report. Onco Targets Ther. 2016;9:4989–92. doi:10.2147/OTT.S110235
   PubMed Web of Science ®Google Scholar
• Li F, Liao Z, Zhao J, Zhao G, Li X, Du X, Yang Y, Yang J. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017;8(38):64471–80.
   PubMedGoogle Scholar
• Zhou Y, Tang F, Wang Y, Min L, Luo Y, Zhang W, Shi R, Duan H, Tu C. Advanced alveolar soft part sarcoma responds to apatinib. Oncotarget. 2017;8(30):50314–22.
   PubMedGoogle Scholar
• Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003;97(10):2544–53. doi:10.1002/cncr.11367
   PubMed Web of Science ®Google Scholar
• Wunder JS, Nielsen TO, Maki RG, O'Sullivan B, Alman BA. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol. 2007;8(6):513–24. doi:10.1016/S1470-2045(07)70169-9
   PubMed Web of Science ®Google Scholar
• Azizi AA, Haberler C, Czech T, Gupper A, Prayer D, Breitschopf H, Acker T, Slavc I. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. Lancet Oncol. 2006;7(6):521–3. doi:10.1016/S1470-2045(06)70729-X
   PubMed Web of Science ®Google Scholar
• Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013;24(1):257–63. doi:10.1093/annonc/mds237
   PubMed Web of Science ®Google Scholar
• Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011;129(8):1963–9. doi:10.1002/ijc.25843
   PubMed Web of Science ®Google Scholar
• Santoro A, Comandone A, Basso U, Soto Parra H, De Sanctis R, Stroppa E, Marcon I, Giordano L, Lutman FR, Boglione A, et al. Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. Ann Oncol. 2013;24(4):1093–8. doi:10.1093/annonc/mds607
   PubMed Web of Science ®Google Scholar
• Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27(19):3133–40. doi:10.1200/JCO.2008.20.4495
   PubMed Web of Science ®Google Scholar
• Penel N, Mir O, Italiano A, Blay J-Y, Wallet J, Bertucci F, Chevreau C, Piperno-Neumann S, Bompas E, Salas S. Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial. Paper presented at: 52nd ASCO Annual Meeting Proceeding; 2016 Jun 3; Chicago.
   Google Scholar
• Berry V, Basson L, Bogart E, Mir O, Blay JY, Italiano A, Bertucci F, Chevreau C, Clisant-Delaine S, Liegl-Antzager B, et al. REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. Cancer. 2017;123(12):2294–302. doi:10.1002/cncr.30661
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schoffski P, Aglietta M, Staddon AP, Beppu Y, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879–86. doi:10.1016/S0140-6736(12)60651-5
   PubMed Web of Science ®Google Scholar
• Yoo KH, Kim HS, Lee SJ, Park SH, Kim SJ, Kim SH, La Choi Y, Shin KH, Cho YJ, Lee J, et al. Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC cancer. 2015;15:154. doi:10.1186/s12885-015-1160-x
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31(26):3219–25. doi:10.1200/JCO.2013.48.8585
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016;34(13):1448–54. doi:10.1200/JCO.2015.63.5995
   PubMed Web of Science ®Google Scholar
• Zhang L, Shi M, Huang C, Liu X, Xiong JP, Chen G, Liu W, Liu W, Zhang Y, Li K. A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens. Paper presented at: 48th ASCO Annual Meeting Proceeding; 2012 June 1; Chicago.
   Google Scholar
• Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135(8):1961–9. doi:10.1002/ijc.28829
   PubMed Web of Science ®Google Scholar
• Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC cancer. 2014;14:820. doi:10.1186/1471-2407-14-820
   PubMed Web of Science ®Google Scholar
• Peng H, Zhang Q, Li J, Zhang N, Hua Y, Xu L, Deng Y, Lai J, Peng Z, Peng B, et al. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget. 2016;7(13):17220–9. doi:10.18632/oncotarget.7948
   PubMed Web of Science ®Google Scholar
• Qin S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. Paper presented at: 50th ASCO Annual Meeting Proceeding; 2014 May 30; Chicago.
   Google Scholar
• Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, Zheng B, Guo W. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 2017;8(8):e3015. doi:10.1038/cddis.2017.422
   PubMed Web of Science ®Google Scholar
• Potti A, Ganti AK, Tendulkar K, Sholes K, Chitajallu S, Koch M, Kargas S. Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma. J Cancer Res Clin Oncol. 2004;130(1):52–6. doi:10.1007/s00432-003-0504-0
   PubMed Web of Science ®Google Scholar
• Han T, Luan Y, Xu Y, Yang X, Li J, Liu R, Li Q, Zheng Z. Successful treatment of advanced pancreatic liposarcoma with apatinib: A case report and literature review. Cancer Biol Ther. 2017;18(9):635–39.
   PubMed Web of Science ®Google Scholar
• Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharma. 2008;3(2):132–43. doi:10.2174/157488408784293705
   PubMedGoogle Scholar
• Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal. 2014;20(1):135–45. doi:10.1089/ars.2013.5244
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar